Tumor DNA sequencing has expanded alternatives for precision oncology, however molecular profiling alone doesn’t at all times clarify therapy resistance or predict therapeutic response. Combining patient-derived three-dimensional (3D) most cancers fashions with useful drug screening and multiomics analyses provides a complementary method for investigating tumor biology and evaluating potential therapy methods in clinically related timeframes.
This poster presentation discusses an built-in workflow that mixes 3D bioprinted colorectal most cancers tumoroids, RNA sequencing, proteomics, and drug response profiling to protect subtype-specific biology, examine resistance mechanisms, and establish various therapeutic approaches for patient-specific analysis.
Watch this poster presentation to study:
- How 3D tumoroid fashions protect subtype-specific tumor biology
- How RNA sequencing and proteomics reveal potential resistance mechanisms
- How built-in drug screening informs various therapeutic hypotheses
